Renal Medullary Carcinoma, A Rare But Aggressive Sickle Cell Nephropathy: A Case Report
DOI:
https://doi.org/10.21276/apalm.3268Keywords:
Renal medullary carcinoma, Sickle Cell Trait, Hemoglobinopathy, PrognosisAbstract
Renal Medullary Carcinoma (RMC) is a highly aggressive cancer that typically affects adults in second to third decades of life with male preponderance and dismal prognosis. As the name indicates, it is medulla centric and is almost exclusively associated with sickle cell hemoglobinopathy. Tumor shows SMARCB1 /INI-1 deficiency and hence called SMARCB1 deficient renal medullary carcinoma. As there are only around 600 cases been reported worldwide till date, we report this case as an eye opener for having high degree of clinical and pathological suspicion in renal cancer patients of younger age, especially if there is no known history of hemoglobinopathy. Prompt diagnosis and treatment is warranted to prolong survival. Our case is that of a 36yr old male who presented with hematuria and loin pain of six months without any significant past history. Radiological evaluation showed right renal mass with extensive metastatic disease. Palliative right radical nephrectomy was done which on thorough histomorphological and immunohistochemical examination was diagnosed as renal medullary carcinoma. Tumor cells showed loss of INI 1 expression which is a surrogate marker for SMARCB1 deficient status. High performance liquid chromatography was done which revealed sickle cell trait. He was started on immunotherapy and chemotherapy, following which he had a favorable treatment response.
References
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022 Nov;82(5):458-68.
Holland P, Merrimen J, Pringle C, Wood LA. Renal medullary carcinoma and its association with sickle cell trait: A case report and literature review. Curr Oncol. 2020;27(1):e53-6.
Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary Carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol. 1995; 19(1):1-11.
Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical Literature. Can Urol Assoc J. 2015; 9(3-4):E172-7.
Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015; 62(10):1694-9.
Alvarez OA. Renal medullary carcinoma: the kidney cancer that affects individuals with sickle cell trait and disease. J Oncol Pract. 2017; 13(7):424-5.
Huang ZM, Wang H, Ji ZG. Renal medullary carcinoma masquerading as renal infection: a case report. BMC Nephrol. 2020; 21(1):79.
Greco F, Faiella E, Santucci D, Mallio CA, Nezzo M, Quattrocchi CC, et al. Imaging of renal medullary Carcinoma. J Kidney Cancer VHL. 2017; 4(1):1-7.
Shetty A, Matrana MR. Renal medullary carcinoma: a case report and brief review of the literature. Ochsner J. 2014 Summer;14(2):270-5.
Severseike BO, Schafernak KT, Willard SD, Goncalves LF, Kothari AK, Eshun FK, et al. Diagnostic challenges of renal medullary carcinoma and the role for cytologic assessment: case report and literature review. J Clin Lab Anal. 2023; 37(4):e24854.
Cheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behaviour. Mod Pathol. 2008 Jun; 21(6):647-52.
Msaouel P, Tannir NM, Walker CL. A model linking sickle cell hemoglobinopathies and smarcb1 loss in renal medullary Carcinoma. Clin Cancer Res. 2018;24(9):2044-9.
Amjad AI, Ali H, Appleman LJ, Maranchie J, Jackman S, Parwani A, et al. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Case Rep Oncol Med. 2014;2014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Lakshmy S Kumar, Vijayalekshmi Nair, K P Aravindan, Narayanankutty Warrier
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
